The platform is a comprehensive biorepository containing over 150,000 samples collected from more than 10,000 patients, with over five years of clinical follow-up. It is designed to address unmet medical needs in liver disease, gastroenterology, and immune-mediated inflammatory conditions. The TARGET-NASH registry, a part of this platform, has alone gathered over 80,000 biospecimen samples.
The platform focuses on diseases with high unmet medical needs and emerging therapies, particularly in areas like liver disease, metabolic dysfunction-associated steatohepatitis (MASH), and immune-mediated inflammatory conditions in dermatology and gastroenterology. The collected bio samples, including serum, whole blood, plasma, and skin tape strips, are obtained through IRB-approved protocols.
This initiative aims to better understand disease progression and assist in genetic and biomarker identification for patient populations. It combines Target RWE’s rich, longitudinal clinical registry data with the biorepository, enhancing the potential for predicting treatment responses and rapid disease progression in patients.
Jennifer Christian, PharmD, PhD, FISPE, Chief Scientific Officer at Target RWE, highlights the significance of this data in generating meaningful insights to improve patient outcomes. Derek Evans, CEO, emphasizes the platform’s role in advancing research design and implementation through predictive analytics capabilities.
Target RWE will also present new data from the TARGET-NASH registry at the NASH-TAG annual conference, focusing on non-invasive tests for assessing MASH resolution score and evaluating cardiovascular risk in NASH/MASH patients.
Overall, the article underscores Target RWE’s commitment to leveraging real-world evidence and advanced analytics to address critical healthcare challenges and improve patient outcomes in liver disease, gastroenterology, and immune-mediated inflammatory conditions.